Literature DB >> 6271823

The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man.

M E Wall, M Perez-Reyes.   

Abstract

The metabolism of delta 9-tetrahydrocannabinol (THC) and related cannabinoids in man has been studied in detail utilizing intravenous, oral, and smoking routes of administration. The general pattern of metabolism was the same in all studies involving THC and related cannabinoids. Microsomal hydroxylation allylic to the delta 9-THC double bond occurs, the major product resulting in formation of an 11-CH2OH moiety; minor hydroxylation occurs on the C-8 carbon. Nonmicrosomal oxidation of the resultant 11-OH-delta 9-THC to 11-nor-delta 9-THC-9-carboxylic acid and to other more polar acids generates the major terminal metabolic products. After oral administration, approximately equal quantities of THC and its highly active 11-hydroxymetabolite were formed, whereas the latter metabolite is a minor constituent after administration by intravenous or smoking routes. Initial pharmacokinetic analyses of the data show that the mean terminal-phase (beta-phase) plasma half-life after intravenous administration of THC was about 30 hours; after oral administration, it was 23 hours. No significant statistical difference was noted between men and women as to metabolic routes or plasma terminal-phase half-lives.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271823     DOI: 10.1002/j.1552-4604.1981.tb02594.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  19 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

Review 2.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

3.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

4.  Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid.

Authors:  David M Schwope; Garry Milman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-04-01       Impact factor: 8.327

5.  Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Authors:  Linda E Klumpers; Tim L Beumer; Johan G C van Hasselt; Astrid Lipplaa; Lennard B Karger; H Daniël Kleinloog; Jan I Freijer; Marieke L de Kam; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

6.  Further studies on the antinociceptive effects of delta 6-THC-7-oic acid.

Authors:  S A Doyle; S H Burstein; W L Dewey; S P Welch
Journal:  Agents Actions       Date:  1990-08

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

9.  8β-OH-THC and 8β,11-diOH-THC-minor metabolites with major informative value?

Authors:  Angela Gasse; Heidi Pfeiffer; Helga Köhler; Jennifer Schürenkamp
Journal:  Int J Legal Med       Date:  2017-10-05       Impact factor: 2.686

10.  Review of cannabinoids and their antiemetic effectiveness.

Authors:  B J Vincent; D J McQuiston; L H Einhorn; C M Nagy; M J Brames
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.